Loading...
XTAE
INCR
Market cap70mUSD
Dec 04, Last price  
419.80ILS
1D
-0.57%
1Q
-22.60%
Jan 2017
65.53%
IPO
-100.00%
Name

InterCure Ltd

Chart & Performance

D1W1MN
XTAE:INCR chart
P/E
P/S
0.96
EPS
Div Yield, %
Shrs. gr., 5y
14.36%
Rev. gr., 5y
92.97%
Revenues
239m
-32.82%
13,226,90612,068,8268,469,3758,250,0425,650,0921,401,4130008,926,00065,035,000219,677,000388,684,000355,553,000238,845,000
Net income
-68m
L+9.42%
0-6,801,32243,441,510000265,4150-12,798,000-2,996,000-36,040,0007,296,00044,819,000-61,959,000-67,795,000
CFO
-67m
L+24.79%
0-860,15600000-921,034-1,486,000-4,013,0007,803,00025,020,00051,267,000-53,631,000-66,926,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
IPO date
Jul 26, 2007
Employees
370
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT